MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, MD, October 14, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-en
How this was made
The 30-second read
Why it matters
The preliminary revenue beat and raised guidance could attract short‑term buying, but the small scale means any price move may be limited.
Market read
First‑report 8‑K guidance raise for a micro‑cap biotech; modest but actionable for traders focused on niche biotech plays.
What to watch
Milestone revenue is non‑recurring and may not repeat; the guidance still reflects a small overall revenue base.
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
Preliminary third-quarter core business revenue increased 26% year over year, and the company raised full-year 2026 guidance for total revenue, core business revenue and SPL Program-related revenue.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Third quarter 2026 core business revenueother | approximately $8.1 million | – | 26% |
| Third quarter 2026 SPL Program-related revenueother | more than $1.0 million | – | – |
| Third quarter 2026 SPL Program milestone revenueother | $1M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Core businessAccelerated instrument purchasing from a large customer, which the company originally anticipated to occur in the fourth quarter. | approximately $8.1 million | – | 26% |
| Strategic Platform License (SPL) ProgramIncluding milestone revenue of $1.0 million received in the third quarter of 2026; royalty revenue will be reported with full financial results on November 10, 2026. | more than $1.0 million | – | – |
Full year 2026 outlook
- Revenueapproximately $34 million
- NoteCore business revenue of approximately $28 million.
- NoteSPL Program-related revenue of approximately $6 million for the year.
- NoteSPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.
- NoteApproximately 15% year-over-year growth in the second half of 2026.
What drove it
- Accelerated instrument purchasing from a large customer drove meaningful third-quarter outperformance.
- The company recognized a milestone from one of its SPL partners, its second milestone achieved in 2026.
- MaxCyte stated that it is supporting more late-stage clinical programs under its SPL partnerships than ever before.
- Two pivotal trials have potential for approval as early as next year.
Concerns
- Third-quarter results are preliminary, unaudited and subject to change in connection with completion of the quarterly closing process and review procedures.
- Preliminary results may differ from actual results reflected in consolidated financial statements for the quarter ended September 30, 2026.
- The company has not yet reported third-quarter royalty revenue.
- Third-quarter core business performance benefited from instrument purchasing that was originally anticipated in the fourth quarter.
What to watch
- Full third-quarter 2026 financial results and royalty revenue, scheduled for November 10, 2026.
- Execution against full-year guidance of approximately $34 million in revenue.
- The timing and contribution of SPL milestone payments and commercial royalties.
- Progression of late-stage clinical programs under SPL partnerships, including two pivotal trials that have potential for approval as early as next year.
Analysis
MaxCyte reported preliminary third-quarter core business revenue of approximately $8.1 million, up 26% compared with the third quarter of 2025. The company attributed meaningful third-quarter outperformance to accelerated instrument purchasing from a large customer. Management said it had originally anticipated that purchasing in the fourth quarter, making purchase timing an important consideration in assessing the reported growth.
SPL Program-related revenue was more than $1.0 million in the third quarter, including $1.0 million of milestone revenue received during the period. The company will report royalty revenue with its full financial results on November 10, 2026, so the filing does not provide a complete third-quarter revenue figure or the full SPL revenue mix. Management said the recognized partner milestone was its second milestone achieved in 2026.
The company raised its full-year 2026 total revenue guidance to approximately $34 million from prior guidance of $30 million to $32 million. Core business revenue guidance increased to approximately $28 million from $25 million to $27 million, while SPL Program-related revenue guidance increased to approximately $6 million from approximately $5 million. The SPL outlook includes approximately $4 million from milestone payments and approximately $2 million from commercial royalties.
Management characterized preliminary third-quarter and total second-half revenue as ahead of expectations and said the revised core business outlook reflects approximately 15% year-over-year growth in the second half of 2026. The company also highlighted a larger set of late-stage clinical programs under SPL partnerships and two pivotal trials that have potential for approval as early as next year. The reported figures remain preliminary, unaudited and subject to change upon completion of the quarterly closing process and review procedures.
The filing does not provide profitability, margins, EPS, cash flow, balance-sheet balances or capital-return figures. The principal upcoming disclosure is the November 10, 2026 earnings release and conference call, when MaxCyte expects to report full third-quarter financial results and royalty revenue.
Management, verbatim
Preliminary third quarter and total second half revenue is ahead of our expectations, and we updated our core business revenue guidance to reflect approximately 15% year-over-year growth in the second half of 2026. We entered into 2026 with the goal of getting back to growth in the second half and we are very encouraged by our return to double-digit growth, with meaningful outperformance in the third quarter driven by accelerated instrument purchasing from a large customer, which we originally anticipated to occur in the fourth quarter. In addition, we raised our SPL Program-related revenue guidance after recognizing a milestone from one of our SPL partners, our second milestone achieved in 2026. We are now supporting more late-stage clinical programs under our SPL partnerships than ever before with two pivotal trials that have potential for approval as early as next year. Overall, we remain focused on executing on our strategic priorities, strengthening our position as a leading enabling technology partner in cell and gene therapy, and building a foundation for sustainable long-term growth.
Maher Masoud, President and CEO
Not in the filing
stated, not guessed- Third-quarter 2026 total revenue, because royalty revenue will be reported with full financial results on November 10, 2026.
- Third-quarter 2026 royalty revenue.
- Prior-year dollar amount for third-quarter 2026 core business revenue.
- Third-quarter 2026 GAAP and non-GAAP gross profit, gross margin, operating expenses, operating income or loss, net income or loss, and EPS.
- Third-quarter 2026 operating cash flow and free cash flow.
- Cash, cash equivalents, debt and other balance-sheet figures.
- Capital-return figures, including share repurchases and dividends.
- Segment revenue beyond core business and SPL Program-related revenue.
- Full-year 2026 guidance for gross margin, operating expenses and tax rate.
- Prior-guidance comparison, because the previous outlook section was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
MaxCyte is a Nasdaq‑listed cell‑engineering firm that provides electroporation platforms for cell‑therapy development.
Ticker impact
MaxCyte issued an 8‑K filing reporting preliminary Q3 2026 revenue and raised its full‑year 2026 revenue guidance to about $34 million.
likely upward pressure as investors price in higher revenue expectations
The company disclosed higher-than‑expected revenue and increased guidance, a fresh primary disclosure that can move the share price.
Market effects
Positive signal for the cell‑engineering and broader biotech sector, indicating demand for platform technologies.
U.S. biotech investors may view the raise as a catalyst for similar platform companies.
Limited to niche biotech space; no broad macro impact.
Counterpoint
The raise may be modest in absolute terms; investors could wait for actual audited results before acting.
Key entities
- ExecutiveMaher Masoud
President and CEO of MaxCyte, quoted on the guidance raise.
